Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America
Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com
New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com
Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Segment 5: Developing Appropriate PRO-PMs
June 29th 2016

Segment 5: Developing Appropriate PRO-PMs

Patient-reported outcome measures help providers and health plans better understand what the patient wants and needs; however, there are still many challenges standing in the way of reaching its full potential, said Jason C. Goldwater, MA, MPA, senior director, National Quality Forum.
Segment 4: Engaging Patients in Care Decisions
June 29th 2016

Segment 4: Engaging Patients in Care Decisions

Linda Bosserman, MD, assistant clinical professor and staff physician, City of Hope, explained that quality measurements allow patients access to important information that can help them make decisions about their care.
Segment 3: Choosing Between Process Measures and Outcomes Measures
June 29th 2016

Segment 3: Choosing Between Process Measures and Outcomes Measures

While the science of quality measurements is still in its infancy, Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, said these metrics have allowed her and her team to open the door of communication among providers on how important quality truly is.
Segment 2: Striking the Balance With Quality Metrics
June 29th 2016

Segment 2: Striking the Balance With Quality Metrics

Jason C. Goldwater, MA, MPA, senior director, National Quality Forum, explained that quality metrics exist for 3 purposes: to ensure the best science and practices are being utilized, to set the bar for what good quality looks like, and to keep up with the evolving nature of healthcare.
Segment 1: Why Do We Measure Healthcare Quality?
June 29th 2016

Segment 1: Why Do We Measure Healthcare Quality?

A provider, a payer, and an expert from an organization that endorses quality measures in healthcare participated in a panel discussion on measuring the quality of care in oncology.
Site Logo
June 29th 2016

OPeN, a Data-Sharing Initiative, Announced Ahead of the Cancer Moonshot Summit

Surabhi Dangi-Garimella, PhD
A newly formed data-sharing initiative, Oncology Precision Network (OPeN), is promising a boost to precision medicine via data access to several health systems and cancer patients in the nation.
Site Logo
June 28th 2016

Paying to Make Health IT Meaningful: A Discussion at the NCCN Policy Summit

Surabhi Dangi-Garimella, PhD
Maximizing the utility of technology platforms and making them meaningful to ensure quality cancer care was the underlying theme of Emerging Issues and Opportunities in Health Information Technology, a National Comprehensive Cancer Network Policy Summit.
Oral Oncolytics: A Look Ahead
June 28th 2016

Oral Oncolytics: A Look Ahead

Value-Based Tools and Real-World Evidence in Oncology
June 28th 2016

Value-Based Tools and Real-World Evidence in Oncology

Payer Management Strategies in Oncology
June 28th 2016

Payer Management Strategies in Oncology

Specialty Pharmacy and Medication Therapy Management in Oncology
June 28th 2016

Specialty Pharmacy and Medication Therapy Management in Oncology

Adherence Strategies and Oral Oncolytics
June 28th 2016

Adherence Strategies and Oral Oncolytics

Next-Generation Sequencing in Oncology
June 28th 2016

Next-Generation Sequencing in Oncology

Oral Oncolytics: Impact of Site of Care
June 28th 2016

Oral Oncolytics: Impact of Site of Care

Access to Oncology Drugs
June 28th 2016

Access to Oncology Drugs

Examining the Total Cost of Cancer Care
June 28th 2016

Examining the Total Cost of Cancer Care

Oral Oncolytics Landscape Across Cancer Types
June 28th 2016

Oral Oncolytics Landscape Across Cancer Types

Site Logo
June 27th 2016

Evidence-Based Oncology Examines Impact of Quality Measures in Cancer Care

What is the best way to measure quality care in cancer? As explored in the current issue of Evidence-Based Oncology, it depends on who you ask, and which tools are used to evaluate care.
Site Logo
June 24th 2016

Choosing Wisely: Healthcare Professionals Need Better Insight on CT Impact

Surabhi Dangi-Garimella, PhD
Exposure of patients to the dangers of certain diagnostic equipment can have unwanted long-term effects, which healthcare providers may be underestimating, according to research conducted at the University of Saskatchewan.
Dr Toby Campbell: Palliative Care Discussions Are Difficult, but Necessary
June 24th 2016

Dr Toby Campbell: Palliative Care Discussions Are Difficult, but Necessary

Bringing up palliative care is inherently difficult for providers, because it means bringing up death and dying, said Toby C. Campbell, MD, MSCI, associate professor of medicine, hematology-oncology at the University of Wisconsin School of Medicine and Public Health.
Site Logo
June 23rd 2016

Health Plans Seek Outcomes-Based Pricing, Says Avalere Study

Surabhi Dangi-Garimella, PhD
A report developed by Avalere Health, based on a survey that the company conducted among health plans in 2015, states that a majority of health plans want to sign outcomes-based contracts with biopharmaceutical companies, especially for oncology and hepatitis C drugs.
Site Logo
June 23rd 2016

PET Scan Can Avoid Toxic Chemotherapy, Improve QoL

Surabhi Dangi-Garimella, PhD
A new study in the New England Journal of Medicine has established that, at least in the case of lymphoma, a positron emission tomography (PET) scan can spare the patients serious side effects of chemotherapy.
Site Logo
June 22nd 2016

ICER to Develop a Value Benchmark for NSCLC Treatment Regimens

Surabhi Dangi-Garimella, PhD
A scoping document explaining the review process to evaluate existing treatment options for non-small cell lung cancer (NSCLC) has been released by the Institute for Clinical and Economic Review (ICER).
Site Logo
June 21st 2016

Oncology Payment Reform: Payers and Providers Discuss APM and Beyond

Surabhi Dangi-Garimella, PhD
An expert panel at The Community Oncology Conference: Innovation in Cancer Care, held in Orlando, Florida, April 13-15, 2016, provided insight on current transitions in healthcare reform, and their predictions for the future.
Site Logo
June 21st 2016

SUNRISE Study Proves Predictive Ability of 12-Gene Colon Cancer Recurrence Assay

Surabhi Dangi-Garimella, PhD
A study assessed the reliability of a 12-gene Recurrence Score test to reveal the natural course of recurrence among Japanese patients with stage II and III colon cancer who have undergone surgery but not received any adjuvant chemotherapy.
Site Logo
June 20th 2016

Surmounting the Quality Chasm in Healthcare

Joseph Alvarnas, MD
Despite the breadth of metrics, there seems to be a significant disconnect between the relatively prosaic, process-based measures that largely dominate our quality portfolio and the high-level, aspiration-driven demands of delivering increasingly complex care to patients with cancer.
Site Logo
June 20th 2016

Biosimilars Can Significantly Reduce Global Healthcare Costs by 2020

Surabhi Dangi-Garimella, PhD
If the announcement by the Swiss pharmaceutical giant Novartis holds true, biosimilars that the company plans to launch over the next 4 years could create a significant dent in the sales of 5 blockbuster molecules in the oncology and immunology space.
Site Logo
June 20th 2016

A Discussion on Oncology Quality Tools: Filling in the Gaps

Surabhi Dangi-Garimella, PhD
Improving the healthcare services that an organization provides can be challenging unless one gathers information on the service, collates it, improves on it, and implements the changes in the field. A panel of experts invited by Evidence-Based Oncology discussed processes that help identify the most valuable metrics and the importance of making them relevant for use in the clinic.
This Week in Managed Care: June 18, 2016
June 18th 2016

This Week in Managed Care: June 18, 2016

This week, the top stories in managed care included study results presented at the 76th Scientific Sessions of the American Diabetes Association from the SWITCH and LEADER trials, a recommendation for a smarter way to screen for prostate cancer, and researchers found physicians underutilize medications to treat opioid addiction.
Site Logo
June 17th 2016

Patient Response to Receiving Genetic Test Results by Phone

Jackie Syrop
Delivering the results of complex genetic tests to at-risk patients over the telephone may be an effective way to reduce burdens and costs for patients with cancer or at risk for cancer and would not cause patients added stress, a study found.
<1
...
979899100101102103104105
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo